vs
Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.6M, roughly 1.2× Marygold Companies, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -60.3%, a 52.8% gap on every dollar of revenue. On growth, Marygold Companies, Inc. posted the faster year-over-year revenue change (-4.5% vs -49.9%). Over the past eight quarters, Marygold Companies, Inc.'s revenue compounded faster (-1.5% CAGR vs -6.7%).
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MGLD vs PLX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.6M | $9.1M |
| Net Profit | $-576.0K | $-5.5M |
| Gross Margin | 74.0% | 49.4% |
| Operating Margin | -8.3% | -51.1% |
| Net Margin | -7.5% | -60.3% |
| Revenue YoY | -4.5% | -49.9% |
| Net Profit YoY | 67.0% | -184.8% |
| EPS (diluted) | $-0.01 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.6M | $9.1M | ||
| Q3 25 | $7.0M | $17.9M | ||
| Q2 25 | $7.2M | $15.7M | ||
| Q1 25 | $7.0M | $10.1M | ||
| Q4 24 | $8.0M | $18.2M | ||
| Q3 24 | $7.9M | $18.0M | ||
| Q2 24 | $8.3M | $13.5M | ||
| Q1 24 | $7.9M | — |
| Q4 25 | $-576.0K | $-5.5M | ||
| Q3 25 | $-356.0K | $2.4M | ||
| Q2 25 | $-1.5M | $164.0K | ||
| Q1 25 | $-1.0M | $-3.6M | ||
| Q4 24 | $-1.7M | $6.5M | ||
| Q3 24 | $-1.6M | $3.2M | ||
| Q2 24 | $-1.9M | $-2.2M | ||
| Q1 24 | $-529.0K | — |
| Q4 25 | 74.0% | 49.4% | ||
| Q3 25 | 77.0% | 53.4% | ||
| Q2 25 | 67.8% | 62.5% | ||
| Q1 25 | 75.0% | 19.1% | ||
| Q4 24 | 74.1% | 78.7% | ||
| Q3 24 | 73.1% | 53.4% | ||
| Q2 24 | 72.5% | 29.8% | ||
| Q1 24 | 70.5% | — |
| Q4 25 | -8.3% | -51.1% | ||
| Q3 25 | -18.2% | 11.9% | ||
| Q2 25 | -16.5% | 7.5% | ||
| Q1 25 | -21.4% | -41.0% | ||
| Q4 24 | -22.8% | 39.6% | ||
| Q3 24 | -27.4% | 22.2% | ||
| Q2 24 | -33.3% | -18.0% | ||
| Q1 24 | -18.7% | — |
| Q4 25 | -7.5% | -60.3% | ||
| Q3 25 | -5.1% | 13.2% | ||
| Q2 25 | -20.4% | 1.0% | ||
| Q1 25 | -14.4% | -35.8% | ||
| Q4 24 | -21.8% | 35.6% | ||
| Q3 24 | -20.1% | 18.0% | ||
| Q2 24 | -22.5% | -16.4% | ||
| Q1 24 | -6.7% | — |
| Q4 25 | $-0.01 | $-0.06 | ||
| Q3 25 | $-0.01 | $0.03 | ||
| Q2 25 | $-0.04 | $0.00 | ||
| Q1 25 | $-0.02 | $-0.05 | ||
| Q4 24 | $-0.04 | $0.10 | ||
| Q3 24 | $-0.04 | $0.03 | ||
| Q2 24 | $-0.05 | $-0.03 | ||
| Q1 24 | $-0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.7M | $48.2M |
| Total Assets | $27.8M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $14.7M | ||
| Q3 25 | $12.5M | $13.6M | ||
| Q2 25 | $12.8M | $17.9M | ||
| Q1 25 | $15.6M | $19.5M | ||
| Q4 24 | $14.9M | $19.8M | ||
| Q3 24 | $17.5M | $27.4M | ||
| Q2 24 | $15.0M | $23.4M | ||
| Q1 24 | $16.1M | — |
| Q4 25 | $22.7M | $48.2M | ||
| Q3 25 | $22.9M | $52.9M | ||
| Q2 25 | $23.0M | $49.9M | ||
| Q1 25 | $24.3M | $45.2M | ||
| Q4 24 | $23.4M | $43.2M | ||
| Q3 24 | $25.5M | $32.4M | ||
| Q2 24 | $26.6M | $28.6M | ||
| Q1 24 | $28.4M | — |
| Q4 25 | $27.8M | $82.3M | ||
| Q3 25 | $28.4M | $82.3M | ||
| Q2 25 | $30.4M | $78.5M | ||
| Q1 25 | $33.5M | $73.9M | ||
| Q4 24 | $33.0M | $73.4M | ||
| Q3 24 | $35.9M | $61.6M | ||
| Q2 24 | $32.9M | $91.5M | ||
| Q1 24 | $33.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-908.0K | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | 0.0% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-908.0K | $2.0M | ||
| Q3 25 | $-533.0K | $-3.7M | ||
| Q2 25 | $-3.3M | $-5.2M | ||
| Q1 25 | $-1.2M | $-5.1M | ||
| Q4 24 | $-770.0K | $4.0M | ||
| Q3 24 | $-893.0K | $4.1M | ||
| Q2 24 | $-1.9M | $-3.6M | ||
| Q1 24 | $-658.0K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | $-562.0K | $-4.2M | ||
| Q2 25 | $-3.4M | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-776.0K | $3.6M | ||
| Q3 24 | $-940.0K | $4.0M | ||
| Q2 24 | $-2.0M | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | -8.1% | -23.7% | ||
| Q2 25 | -46.8% | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | -9.7% | 19.6% | ||
| Q3 24 | -11.9% | 22.4% | ||
| Q2 24 | -23.8% | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 4.4% | ||
| Q3 25 | 0.4% | 2.8% | ||
| Q2 25 | 0.7% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.6% | 0.5% | ||
| Q2 24 | 0.7% | 1.3% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
